5 results
DEF 14A
NMRA
Neumora Therapeutics, Inc. Common Stock
25 Apr 24
Definitive proxy
4:05pm
The following table represents aggregate fees billed by EY relating to the fiscal years ended December 31, 2023 and 2022.
Year Ended December 31, | ||||||||
2023 | 2022 | |||||||
Audit Fees(1) | $ | 1,306,202 | $ | 1,066,891 | ||||
Audit-Related Fees | — | — | ||||||
Tax Fees | 174,866 | 76,735 | ||||||
All Other Fees | — | — | ||||||
Total Fees | $ | 1,481,068 | $ | 1,143,626 |
10-K
2023 FY
NMRA
Neumora Therapeutics, Inc. Common Stock
7 Mar 24
Annual report
4:05pm
Amount | Expiration Years | |||||
NOLs, federal (post-December 31, 2017) | $ | 273,262 | Indefinite (1) | |||
NOLs, federal (pre-January 1, 2018) | 40,370 | 2034 through 2036 | ||||
NOLs, state | 251,417 | 2034 thru 2043 | ||||
Research and development tax credits, federal | 12,202 | 2034 thru 2043 | ||||
Research and development tax credits, California | 4,408 | Indefinite | ||||
Research and development tax credits, Massachusetts | 1,002 | 2034 thru 2038 |
10-K
2023 FY
NMRA
Neumora Therapeutics, Inc. Common Stock
7 Mar 24
Annual report
4:05pm
December 31, | ||||||||
2023 | 2022 | |||||||
(in thousands) | ||||||||
Beginning balance of unrecognized tax benefits | $ | 8,176 | $ | 7,821 | ||||
Gross increases based on tax positions related to current year | 391 | 355 | ||||||
Gross increases based on tax positions related to prior years | 97 | — | ||||||
Ending balance of unrecognized tax benefits | $ | 8,664 | $ | 8,176 |
10-K
2023 FY
NMRA
Neumora Therapeutics, Inc. Common Stock
7 Mar 24
Annual report
4:05pm
Year Ended December 31, | ||||||||
2023 | 2022 | |||||||
(in thousands) | ||||||||
Deferred tax assets: | ||||||||
Net operating losses | $ | 79,117 | $ | 63,937 | ||||
Capitalized license agreements | 41,032 | 39,113 | ||||||
Capitalized research and development expense | 57,872 | 26,132 | ||||||
Research and development credits | 12,981 | 8,425 | ||||||
Compensation related | 5,942 | 3,496 | ||||||
Operating lease liabilities | 1,429 | 2,080 | ||||||
Other | 407 | 467 | ||||||
Total deferred tax assets | 198,780 | 143,650 | ||||||
Less: valuation allowance | (197,280) | (141,557) | ||||||
Total deferred tax assets less valuation allowance | 1,500 | 2,093 | ||||||
Deferred tax liabilities: | ||||||||
Operating lease right-of-use assets | (1,385) | (2,028) | ||||||
Fixed assets | (115) | (65) | ||||||
Total deferred tax liabilities | (1,500) | (2,093) | ||||||
Net deferred tax assets | $ | — | $ | — |
10-K
2023 FY
NMRA
Neumora Therapeutics, Inc. Common Stock
7 Mar 24
Annual report
4:05pm
Year Ended December 31, | ||||||||||
2023 | 2022 | |||||||||
(in thousands) | ||||||||||
Federal income taxes | 21.0 | % | 21.0 | % | ||||||
State income taxes, net of federal benefit | 2.8 | 3.7 | ||||||||
Milestone payments | (5.3) | — | ||||||||
Permanent differences | (0.9) | (0.5) | ||||||||
Research and development tax credits | 2.1 | 2.1 | ||||||||
Tax law change | 3.6 | — | ||||||||
State rate adjustment | 0.5 | 2.2 | ||||||||
Uncertain tax positions | (0.2) | (0.3) | ||||||||
Valuation allowance | (23.7) | (28.2) | ||||||||
Effective income tax rate | (0.1) | % | — | % |
- Prev
- 1
- Next